Fuyuan Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for loxoprofen sodium patches issued by the State Drug Administration and approved the production of the drug. This medicine is used to reduce inflammation and pain due to osteoarthritis, muscle pain, and swelling or pain due to trauma. The company received a notice of acceptance of the application on April 24, 2024. The total R&D investment as of the announcement date was RMB 11.7065 million.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.